544 related articles for article (PubMed ID: 31785413)
21. Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review.
Lavoie JM; Black PC; Eigl BJ
J Urol; 2019 Jul; 202(1):49-56. PubMed ID: 30730407
[TBL] [Abstract][Full Text] [Related]
22. Which place for avelumab in the management of urothelial carcinoma?
Larroquette M; Gross-Goupil M; Daste A; Robert G; Ravaud A; Domblides C
Expert Opin Biol Ther; 2019 Sep; 19(9):863-870. PubMed ID: 31286802
[No Abstract] [Full Text] [Related]
23. PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives.
Gevaert T; Cimadamore A; Montironi R; Eckstein M
Curr Drug Targets; 2021; 22(2):162-170. PubMed ID: 32386490
[TBL] [Abstract][Full Text] [Related]
24. Role of Checkpoint Inhibition in Localized Bladder Cancer.
Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
[TBL] [Abstract][Full Text] [Related]
25. Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States.
Criss SD; Weaver DT; Sheehan DF; Lee RJ; Pandharipande PV; Kong CY
Urol Oncol; 2019 Mar; 37(3):180.e11-180.e18. PubMed ID: 30528699
[TBL] [Abstract][Full Text] [Related]
26. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
[TBL] [Abstract][Full Text] [Related]
27. Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
Sonpavde G; Manitz J; Gao C; Tayama D; Kaiser C; Hennessy D; Makari D; Gupta A; Abdullah SE; Niegisch G; Rosenberg JE; Bajorin DF; Grivas P; Apolo AB; Dreicer R; Hahn NM; Galsky MD; Necchi A; Srinivas S; Powles T; Choueiri TK; Pond GR
J Urol; 2020 Dec; 204(6):1173-1179. PubMed ID: 32552295
[TBL] [Abstract][Full Text] [Related]
28. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.
Davis AA; Patel VG
J Immunother Cancer; 2019 Oct; 7(1):278. PubMed ID: 31655605
[TBL] [Abstract][Full Text] [Related]
29. Expressions of PD-L1 and Nectin-4 in urothelial cancer patients treated with pembrolizumab.
Ueki H; Hinata N; Kitagawa K; Hara T; Terakawa T; Furukawa J; Harada K; Nakano Y; Komatsu M; Fujisawa M; Shirakawa T
Clin Transl Oncol; 2022 Mar; 24(3):568-577. PubMed ID: 34687441
[TBL] [Abstract][Full Text] [Related]
30. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.
Koshkin VS; Grivas P
Curr Oncol Rep; 2018 Apr; 20(6):48. PubMed ID: 29644490
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 testing in urothelial bladder cancer: essentials of clinical practice.
Rouanne M; Radulescu C; Adam J; Allory Y
World J Urol; 2021 May; 39(5):1345-1355. PubMed ID: 33141317
[TBL] [Abstract][Full Text] [Related]
32. Outcomes With First-line PD-1/PD-L1 Inhibition in Advanced Urothelial Cancer: A Single Institution Experience.
Hsu MM; Xia Y; Troxel A; Delbeau D; Francese K; Leis D; Shepherd D; Balar AV
Clin Genitourin Cancer; 2020 Jun; 18(3):e209-e216. PubMed ID: 32253170
[TBL] [Abstract][Full Text] [Related]
33. Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.
Niglio SA; Jia R; Ji J; Ruder S; Patel VG; Martini A; Sfakianos JP; Marqueen KE; Waingankar N; Mehrazin R; Wiklund P; Oh WK; Mazumdar M; Ferket BS; Galsky MD
Eur Urol; 2019 Dec; 76(6):782-789. PubMed ID: 31200951
[TBL] [Abstract][Full Text] [Related]
34. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
35. Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab.
Vennapusa B; Baker B; Kowanetz M; Boone J; Menzl I; Bruey JM; Fine G; Mariathasan S; McCaffery I; Mocci S; Rost S; Smith D; Dennis E; Tang SY; Damadzadeh B; Walker E; Hegde PS; Williams JA; Koeppen H; Boyd Z
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):92-100. PubMed ID: 29346180
[TBL] [Abstract][Full Text] [Related]
36. Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Hersom M; Jørgensen JT
Ther Drug Monit; 2018 Feb; 40(1):9-16. PubMed ID: 29084031
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas.
Huang RSP; Haberberger J; Harries L; Severson E; Duncan DL; Ferguson NL; Hemmerich A; Edgerly C; Murugesan K; Xiao J; McEwan D; Holmes O; Hiemenz M; Venstrom J; Elvin JA; Creeden J; Lin DI; Ross JS; Ramkissoon SH
Oncologist; 2021 May; 26(5):375-382. PubMed ID: 33687775
[TBL] [Abstract][Full Text] [Related]
38. PD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical Trials.
Hsu MM; Balar AV
Clin Genitourin Cancer; 2019 Jun; 17(3):e618-e626. PubMed ID: 31005473
[TBL] [Abstract][Full Text] [Related]
39. Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis.
Liu H; Ye T; Yang X; Lv P; Wu X; Zhou H; Lu H; Tang K; Ye Z
Dis Markers; 2020; 2020():8375348. PubMed ID: 32685057
[TBL] [Abstract][Full Text] [Related]
40. Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer.
Stühler V; Maas JM; Bochem J; da Costa IA; Todenhöfer T; Stenzl A; Bedke J
World J Urol; 2019 Sep; 37(9):1773-1784. PubMed ID: 30374610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]